DiWB-1: A Targeted Approach to Prostate Cancer Treatment

DiWB-1, a luteinizing hormone-releasing hormone (LHRH)-targeted peptide-drug conjugate (PDC) with PI3K inhibition properties, is an emerging candidate that may offer a new way to treat prostate cancer. Its design and mechanism suggest potential for addressing some of the limitations of current treatments, particularly for resistant cases.

DiWB-1 is described as an LHRH-targeted PDC, a class of therapeutics that combines a peptide targeting specific receptors with a drug payload to enhance tumor selectivity. In this case, DiWB-1 targets LHRH receptors, which are overexpressed on prostate cancer cells, to deliver a PI3K inhibitor. The PI3K/AKT/mTOR pathway is a key driver of cancer cell survival and proliferation, particularly in CRPC, where it contributes to resistance against ADT. By focusing the drug’s action on cancer cells, DiWB-1 aims to reduce systemic toxicity and improve efficacy compared to non-targeted therapies.

Its design aligns with the growing field of PDCs. These conjugates are gaining attention for their ability to penetrate tissues effectively and minimize off-target effects, as noted in recent reviews Peptide–Drug Conjugates as Next-Generation Therapeutics.

Prostate cancer cells often express high levels of LHRH receptors, making them a viable target for therapies like DiWB-1. The LHRH component guides the drug to cancer cells, where the PI3K inhibitor can disrupt a pathway critical for tumor growth, especially in cases resistant to ADT.
PI3K inhibition is particularly relevant for CRPC, where the PI3K/AKT/mTOR pathway is often activated, driving resistance to therapies that lower androgen levels. Non-targeted PI3K inhibitors, like buparlisib, have shown limited success due to toxicity and resistance, but DiWB-1’s targeted delivery could improve outcomes by concentrating the drug’s effects on cancer cells Targeting PI3K in cancer: mechanisms and advances.

DiWB-1’s mechanism suggests it could play a role in treating prostate cancer, particularly for patients who no longer respond to ADT. By targeting LHRH receptors and inhibiting PI3K, it addresses both the hormonal and resistance pathways, potentially offering benefits over ADT in specific contexts. For instance, preclinical data on similar PDCs, like AN-152, show reduced tumor volumes with lower toxicity in LHRH-receptor-positive cancers, though results in prostate cancer are less documented.

Source.